ライフサイエンスコーパス: measles vaccine

1 ide despite the availability of an effective measles vaccine.

2 s seroconverted after receiving two doses of measles vaccine.

3 of life, which affects the immunogenicity of measles vaccine.

4 who were eligible to receive a first dose of measles vaccine.

5 ide despite the availability of an effective measles vaccine.

6 ratios (HRRs) for measles vaccine versus no measles vaccine.

7 efore the introduction and widespread use of measles vaccine.

8 ussis vaccine dose 1 (DTP1), DTP2, DTP3, and measles vaccine.

9 receive the current licensed live attenuated measles vaccine.

10 into the ontogeny of the immune response to measles vaccine.

11 es were in grades requiring a second dose of measles vaccine.

12 nuated measles virus are in use worldwide as measles vaccines.

13 lly worldwide before the introduction of the measles vaccines.

14 ung to receive currently licensed attenuated measles vaccines.

15 hs; 8 weeks-4 months; 12 weeks-6 months) and measles vaccine (38 weeks-12 months).

16 subjects had received the post-1980 Moraten measles vaccine 4 to 11 years earlier.

17 ly significant effect on immune responses to measles vaccine; 61 of 970 (6.3%) children who received

18 lowest if IPV is administered with DTP3 and measles vaccine (69%) and highest if administered with D

19 After 2 doses of measles vaccine, 98.2% of all subjects in this study wer

20 The demand for measles vaccine across populations driven by individual

21 in 70 children aged 5-10 years after primary measles vaccine administered at 6, 9, or 12 months.

22 tudy of the immunogenicity of standard-titer measles vaccine administered at 9 months of age to HIV-1

23 receive measles vaccine at 4.5 months or no measles vaccine; all children were offered measles vacci

24 For example, the live attenuated measles vaccine and BCG vaccine may reduce mortality fro

25 infants when administered concomitantly with measles vaccine and PsA-TT.

26 inbred cotton rats which were infected with measles vaccine and wild-type viruses.

27 ine (DPT3) and those who were immunized with measles vaccine, and comparing their values to those obt

28 en a national goal since the introduction of measles vaccine, and measles surveillance has been cruci

29 estimate effectiveness of Romanian-produced measles vaccine, and to evaluate age at vaccination and

30 agnostic tests are available, and attenuated measles vaccines are effective and immunogenic.

31 ed infants to this problem, more immunogenic measles vaccines are highly desirable.

32 the introduction of a second routine dose of measles vaccine as a combined measles-mumps-rubella (MMR

33 is vaccine were randomly assigned to receive measles vaccine at 4.5 months or no measles vaccine; all

34 sing serum samples from infants who received measles vaccine at 6 months of age and measles-mumps-rub

35 recommendation to administer a first dose of measles vaccine at 6 months of age to HIV-infected child

36 rubella (MMR)-II at 12 months of age (n=26), measles vaccine at 9 months of age and measles-mumps-rub

37 o measles vaccine; all children were offered measles vaccine at 9 months of age.

38 Fifty-five infants were vaccinated with measles vaccine at age 6 (n=32) or 9 (n=23) months, foll

39 Children received measles vaccine at age 9 months and measles-rubella vacc

40 One dose of measles vaccine at age 9 months was highly immunogenic.

41 nicity of 2 vaccination regimens: monovalent measles vaccine (Attenuvax) at 6 months of age and measl

42 est that administration of the first dose of measles vaccine before 15 months of age may not be optim

43 dation that countries reach 80% coverage for measles vaccine before introducing rubella vaccination,

44 ine, three doses of pentavalent vaccine, and measles vaccine) by 12 months of age constituted the pri

45 on has on immune responses to measles and to measles vaccine can impact measles elimination efforts.

46 ar immunisation with a candidate recombinant measles vaccine carrying an HIV-1 insert encoding Clade

47 incidence decreased rapidly with increasing measles vaccine coverage and became low or negligible wh

48 sles in 2002 through high first-dose routine measles vaccine coverage and vaccination campaigns every

49 The gap in measles vaccine coverage between white and nonwhite chil

50 While measles vaccine coverage has increased markedly, signifi

51 that each country in the subregion maintains measles vaccine coverage of >/=95%.

52 We also examined data on routine and SIA measles vaccine coverage, measles case-based surveillanc

53 er with respect to median routine first-dose measles vaccine coverage, median coverage for 3 measles

54 atened by failure to maintain high levels of measles vaccine coverage.

55 macaques immunized with formalin-inactivated measles vaccine developed transient neutralizing and fus

56 Thus, live attenuated measles vaccines differ in replicative capacity and path

57 sed on earlier administration of their first measles vaccine dose at </=12 vs >/=15 months of age.

58 Among 5542 children given a first measles vaccine dose at 11, 12, 13-14, and 15-22 months

59 nicity data among children given their first measles vaccine dose between 11 and 22 months of age wer

60 Negative effects of earlier age at first measles vaccine dose persisted after the second dose.

61 not respond reliably to the live attenuated measles vaccine due the immaturity of their immune syste

62 Information on measles vaccine effectiveness (VE) is critical to help i

63 es (ARs) by vaccination status and estimated measles vaccine effectiveness as 1 - [ARvaccinated/ARunv

64 Ws) by assessing laboratory characteristics, measles vaccine effectiveness, and serological correlate

65 y was deficient in 6-month-old infants given measles vaccine, even in the absence of detectable passi

66 In the 1960s, a formalin-inactivated measles vaccine (FIMV) predisposed recipients to atypica

67 ated with LAV or with a formalin-inactivated measles vaccine (FIMV).

68 erage for both the first and second doses of measles vaccine for all local populations; developing de

69 jecting polio vaccine, 38% of mothers sought measles vaccine for their children.

70 measles viruses (MV) expressing HBsAg retain measles vaccine function in monkeys but do not induce a

71 Following enrollment, the measles vaccine group had an admission HRR of 0.70 (95%

72 In the United States, measles vaccine has been given at age 12 to 15 months to

73 ials from low-income countries indicate that measles vaccine has beneficial nonspecific effects, prot

74 T cell responses important for evaluation of measles vaccines, human leukocyte antigen (HLA)-A2-posit

75 Cytokines are key regulators of measles vaccine humoral and cellular immunity.

76 the United States since the introduction of measles vaccine in 1963.

77 Avidity and isotype maturation of measles vaccine-induced antibody are affected by age, pr

78 Ps in the IL-2, IL-10, and IL-12RB genes and measles vaccine-induced immunity.

79 ces in cytokine levels should also influence measles vaccine-induced immunity.

80 .001), whereas GMCs increased with older age measles vaccine initiation (P < .001).

81 Several potential measles vaccine innovations are in development to addres

82 Because measles vaccine is delivered by injection, hurdles to hi

83 dose measles immunization schedule, in which measles vaccine is given at 12 and 18 months of age, had

84 Third, a second dose of measles vaccine is needed to achieve satisfactory levels

85 Early measles vaccine may have major benefits for infant morbi

86 Children in Guinea-Bissau receive measles vaccine (MV) at 9 months of age, but studies hav

87 th Organization recommends administration of measles vaccine (MV) at age 9 months in low-income count

88 y demonstrated the efficacy of a recombinant measles vaccine (MV) expressing the secreted form of the

89 Measles vaccine (MV) has a greater effect on child survi

90 inst nonvaccine infections, as described for measles vaccine (MV), or increased susceptibility to inf

91 single unit dose, dry powder live-attenuated measles vaccine (MVDP) for respiratory delivery without

92 primarily in developed countries) shows that measles vaccine performs in these settings as anticipate

93 It is not known whether measles vaccine protects against hospital admissions.

94 In low-income countries, live measles vaccine reduces mortality from causes other than

95 rtality support the study of an early 2-dose measles vaccine regimen.

96 ms involved in the attenuation of individual measles vaccines remain to be elucidated, in vitro assay

97 After the first and second doses of measles vaccine, respectively, the percentages of childr

98 atitis virus, alphavirus-based chimeras, and measles vaccine Schwarz strain (MV/Schw) have been descr

99 a rapid, easily adoptable method to identify measles vaccine strains in suspect cases.

100 uantitative PCR [RT-qPCR]) that can identify measles vaccine strains rapidly, with high throughput, a

101 The complete genomic sequences of 9 measles vaccine strains were compared with the sequence

102 iting a cell-mediated immune response in new measles vaccine strategies.

103 Pursuing a new measles vaccine strategy that might be effective in youn

104 bias were also lower when using results for measles vaccine than for DPT3, suggesting that the measl

105 dies were more likely to have never received measles vaccine than those with antibodies (adjusted OR

106 hat the discrepancy between the coverages of measles vaccine that are driven by self-interest and tho

107 There is a need for a measles vaccine that can be administered at birth in the

108 en showed good primary antibody responses to measles vaccine, their rapid waning of antibody suggests

109 stagnating global coverage with two doses of measles vaccine through advocacy, education, and the str

110 re being investigated as a new generation of measles vaccine to protect infants too young to receive

111 me highlights the transition from monovalent measles vaccine to the incorporation of measles-mumps-ru

112 ied as measles cases; 6 were vaccinated with measles vaccine twice, 1 was vaccinated once, and 1 was

113 ding admission hazard rate ratios (HRRs) for measles vaccine versus no measles vaccine.

114 ted by immunization with the live attenuated measles vaccine virus.

115 s, the estimated effectiveness of 2 doses of measles vaccine was 52% (95% confidence interval [CI], -

116 Both studies indicated that measles vaccine was highly effective.

117 Monovalent measles vaccine was introduced in 1977, and measles vacc

118 dy seronegative or equivocal after 1 dose of measles vaccine were entered into the trial and reimmuni

119 ith antibody titers >120 mIU after the first measles vaccine were lower in infants vaccinated at age

120 ility that immunisation with live attenuated measles vaccine, which induces active immunity to measle

121 ore, the specific proteins included in a new measles vaccine will affect the type of cytokine respons

122 tates, partly because of the assumption that measles vaccines will continue to be delivered in respon